The suppression of HO formation by palovarotene, an RARγ agonist, in individuals with FOP is accompanied by a reduced expression of Inhba, the gene encoding Activin A, further supporting a role for Activin A in the molecular pathogenesis of FOP [53]. This evidence concerns the gene RARG and fibrodysplasia ossificans progressiva.